MDC’s first patented technology licensed to Selvita
13 Jun 2025
Contract research organisation Selvita has become the first CRO to license the Medicines Discovery Catapult’s technology for prioritising drug candidates.
The MDC’s chemical protein stability assay assesses target engagement for early stage drug discovery, in order to speed the process of finding viable drug candidates.
While target engagement assays normally involve multiple processing steps and can introduce variability, the MDC assay provides a single-plate format for consistency and throughput.
After securing the licence, Selvita is now integrating the assay – the MDC’s first patented technology – into its operations.
MDC chief commercial officer Dr Francesca Sadler said:
“The CPSA is the first technology MDC has patented, and we are delighted to provide this additional tool for drug discovery innovators to overcome some of the barriers in early-stage drug discovery.
“In doing so, MDC is helping to drive productivity and impact, accelerating the path to commercial success and getting more medicines to patients faster.”
Pic: MDC
